434 related articles for article (PubMed ID: 26636418)
1. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia.
Caserini M; Radicioni M; Leuratti C; Terragni E; Iorizzo M; Palmieri R
Int J Clin Pharmacol Ther; 2016 Jan; 54(1):19-27. PubMed ID: 26636418
[TBL] [Abstract][Full Text] [Related]
2. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers.
Caserini M; Radicioni M; Leuratti C; Annoni O; Palmieri R
Int J Clin Pharmacol Ther; 2014 Oct; 52(10):842-9. PubMed ID: 25074865
[TBL] [Abstract][Full Text] [Related]
3. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L; Hordinsky M; Fiedler V; Swinehart J; Unger WP; Cotterill PC; Thiboutot DM; Lowe N; Jacobson C; Whiting D; Stieglitz S; Kraus SJ; Griffin EI; Weiss D; Carrington P; Gencheff C; Cole GW; Pariser DM; Epstein ES; Tanaka W; Dallob A; Vandormael K; Geissler L; Waldstreicher J
J Am Acad Dermatol; 1999 Oct; 41(4):550-4. PubMed ID: 10495374
[TBL] [Abstract][Full Text] [Related]
4. The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness.
Dallob AL; Sadick NS; Unger W; Lipert S; Geissler LA; Gregoire SL; Nguyen HH; Moore EC; Tanaka WK
J Clin Endocrinol Metab; 1994 Sep; 79(3):703-6. PubMed ID: 8077349
[TBL] [Abstract][Full Text] [Related]
5. MK-386, an inhibitor of 5alpha-reductase type 1, reduces dihydrotestosterone concentrations in serum and sebum without affecting dihydrotestosterone concentrations in semen.
Schwartz JI; Tanaka WK; Wang DZ; Ebel DL; Geissler LA; Dallob A; Hafkin B; Gertz BJ
J Clin Endocrinol Metab; 1997 May; 82(5):1373-7. PubMed ID: 9141518
[TBL] [Abstract][Full Text] [Related]
6. [Therapy of androgenetic alopecia with finasteride. What must be considered in consultation and drug prescribing].
Wolff H; Kunte C
MMW Fortschr Med; 1999 Sep; 141(37):38-40. PubMed ID: 10897972
[TBL] [Abstract][Full Text] [Related]
7. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group.
Kaufman KD; Olsen EA; Whiting D; Savin R; DeVillez R; Bergfeld W; Price VH; Van Neste D; Roberts JL; Hordinsky M; Shapiro J; Binkowitz B; Gormley GJ
J Am Acad Dermatol; 1998 Oct; 39(4 Pt 1):578-89. PubMed ID: 9777765
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Ryu HK; Kim KM; Yoo EA; Sim WY; Chung BC
Br J Dermatol; 2006 Apr; 154(4):730-4. PubMed ID: 16536818
[TBL] [Abstract][Full Text] [Related]
9. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
Olsen EA; Hordinsky M; Whiting D; Stough D; Hobbs S; Ellis ML; Wilson T; Rittmaster RS;
J Am Acad Dermatol; 2006 Dec; 55(6):1014-23. PubMed ID: 17110217
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia.
Suchonwanit P; Srisuwanwattana P; Chalermroj N; Khunkhet S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2257-2263. PubMed ID: 29972712
[TBL] [Abstract][Full Text] [Related]
11. Lack of efficacy of finasteride in postmenopausal women with androgenetic alopecia.
Price VH; Roberts JL; Hordinsky M; Olsen EA; Savin R; Bergfeld W; Fiedler V; Lucky A; Whiting DA; Pappas F; Culbertson J; Kotey P; Meehan A; Waldstreicher J
J Am Acad Dermatol; 2000 Nov; 43(5 Pt 1):768-76. PubMed ID: 11050579
[TBL] [Abstract][Full Text] [Related]
12. Caspase-1 level is higher in the scalp in androgenetic alopecia.
de Rivero Vaccari JP; Sawaya ME; Brand F; Nusbaum BP; Bauman AJ; Bramlett HM; Dietrich WD; Keane RW
Dermatol Surg; 2012 Jul; 38(7 Pt 1):1033-9. PubMed ID: 22404322
[TBL] [Abstract][Full Text] [Related]
13. Ketocazole as an adjunct to finasteride in the treatment of androgenetic alopecia in men.
Hugo Perez BS
Med Hypotheses; 2004; 62(1):112-5. PubMed ID: 14729013
[TBL] [Abstract][Full Text] [Related]
14. Hair growth effects of oral administration of finasteride, a steroid 5 alpha-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque.
Diani AR; Mulholland MJ; Shull KL; Kubicek MF; Johnson GA; Schostarez HJ; Brunden MN; Buhl AE
J Clin Endocrinol Metab; 1992 Feb; 74(2):345-50. PubMed ID: 1309834
[TBL] [Abstract][Full Text] [Related]
15. An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia.
Arca E; Açikgöz G; Taştan HB; Köse O; Kurumlu Z
Dermatology; 2004; 209(2):117-25. PubMed ID: 15316165
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of Topical Finasteride in the Treatment of Androgenetic Alopecia in Men and Women.
Lee SW; Juhasz M; Mobasher P; Ekelem C; Mesinkovska NA
J Drugs Dermatol; 2018 Apr; 17(4):457-463. PubMed ID: 29601622
[TBL] [Abstract][Full Text] [Related]
17. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study.
Shanshanwal SJ; Dhurat RS
Indian J Dermatol Venereol Leprol; 2017; 83(1):47-54. PubMed ID: 27549867
[TBL] [Abstract][Full Text] [Related]
18. Clinical dose ranging studies with finasteride, a type 2 5alpha-reductase inhibitor, in men with male pattern hair loss.
Roberts JL; Fiedler V; Imperato-McGinley J; Whiting D; Olsen E; Shupack J; Stough D; DeVillez R; Rietschel R; Savin R; Bergfeld W; Swinehart J; Funicella T; Hordinsky M; Lowe N; Katz I; Lucky A; Drake L; Price VH; Weiss D; Whitmore E; Millikan L; Muller S; Gencheff C
J Am Acad Dermatol; 1999 Oct; 41(4):555-63. PubMed ID: 10495375
[TBL] [Abstract][Full Text] [Related]
19. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer.
Stanczyk FZ; Azen CG; Pike MC
J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436
[TBL] [Abstract][Full Text] [Related]
20. Change in Prostate Specific Antigen Concentration in Men with Prostate Specific Antigen Less than 2.5 ng/ml Taking Low Dose Finasteride or Dutasteride for Male Androgenetic Alopecia.
Kang HW; Chae MH; Park SH; Seo SP; Kim WT; Kim YJ; Yun SJ; Lee SC; Yoon TY; Kim WJ
J Urol; 2017 Dec; 198(6):1340-1345. PubMed ID: 28743526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
